ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Published Date: 03 Jun 2025

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

2.

The Kansas Cancer Center awarded two Indian American doctors professorships.

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

5.

Using AI, one can find cancer risk factors.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot